KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Short term Debt (2023 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Short term Debt for 3 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • Quarterly Short term Debt rose 436.65% to $4.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Dec 2025, up 436.65% year-over-year, with the annual reading at $4.6 million for FY2025, 436.65% up from the prior year.
  • Short term Debt hit $4.6 million in Q4 2025 for Adaptive Biotechnologies, up from $2.4 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $4.6 million in Q4 2025 to a low of $865000.0 in Q4 2024.
  • Historically, Short term Debt has averaged $2.7 million across 3 years, with a median of $2.7 million in 2025.
  • Biggest YoY gain for Short term Debt was 436.65% in 2025; the steepest drop was 436.65% in 2025.
  • Year by year, Short term Debt stood at $3.2 million in 2023, then tumbled by 72.92% to $865000.0 in 2024, then soared by 436.65% to $4.6 million in 2025.
  • Business Quant data shows Short term Debt for ADPT at $4.6 million in Q4 2025, $2.4 million in Q3 2025, and $3.1 million in Q2 2025.